FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361954280> ?p ?o ?g. }

• W4361954280 abstract "<div>AbstractPurpose:<p>PARP inhibitors (PARPi) induce synthetic lethality in homologous recombination repair (HRR)-deficient tumors and are used to treat breast, ovarian, pancreatic, and prostate cancers. Multiple PARPi resistance mechanisms exist, most resulting in restoration of HRR and protection of stalled replication forks. ATR inhibition was highlighted as a unique approach to reverse both aspects of resistance. Recently, however, a PARPi/WEE1 inhibitor (WEE1i) combination demonstrated enhanced antitumor activity associated with the induction of replication stress, suggesting another approach to tackling PARPi resistance.</p>Experimental Design:<p>We analyzed breast and ovarian patient-derived xenoimplant models resistant to PARPi to quantify WEE1i and ATR inhibitor (ATRi) responses as single agents and in combination with PARPi. Biomarker analysis was conducted at the genetic and protein level. Metabolite analysis by mass spectrometry and nucleoside rescue experiments <i>ex vivo</i> were also conducted in patient-derived models.</p>Results:<p>Although WEE1i response was linked to markers of replication stress, including <i>STK11/RB1</i> and phospho-RPA, ATRi response associated with <i>ATM</i> mutation. When combined with olaparib, WEE1i could be differentiated from the ATRi/olaparib combination, providing distinct therapeutic strategies to overcome PARPi resistance by targeting the replication stress response. Mechanistically, WEE1i sensitivity was associated with shortage of the dNTP pool and a concomitant increase in replication stress.</p>Conclusions:<p>Targeting the replication stress response is a valid therapeutic option to overcome PARPi resistance including tumors without an underlying HRR deficiency. These preclinical insights are now being tested in several clinical trials where the PARPi is administered with either the WEE1i or the ATRi.</p></div>" @default.
• W4361954280 created "2023-04-05" @default.
• W4361954280 creator A5008174510 @default.
• W4361954280 creator A5012973903 @default.
• W4361954280 creator A5013805263 @default.
• W4361954280 creator A5018587370 @default.
• W4361954280 creator A5021169552 @default.
• W4361954280 creator A5021762206 @default.
• W4361954280 creator A5022677387 @default.
• W4361954280 creator A5023192928 @default.
• W4361954280 creator A5024721415 @default.
• W4361954280 creator A5028333558 @default.
• W4361954280 creator A5031229355 @default.
• W4361954280 creator A5033987639 @default.
• W4361954280 creator A5037908617 @default.
• W4361954280 creator A5040450413 @default.
• W4361954280 creator A5045263771 @default.
• W4361954280 creator A5047370165 @default.
• W4361954280 creator A5049869363 @default.
• W4361954280 creator A5053506379 @default.
• W4361954280 creator A5053924692 @default.
• W4361954280 creator A5055277039 @default.
• W4361954280 creator A5057710096 @default.
• W4361954280 creator A5058717267 @default.
• W4361954280 creator A5067794408 @default.
• W4361954280 creator A5069830252 @default.
• W4361954280 creator A5070823369 @default.
• W4361954280 creator A5071581968 @default.
• W4361954280 creator A5073423716 @default.
• W4361954280 creator A5076118281 @default.
• W4361954280 creator A5076784474 @default.
• W4361954280 creator A5077169627 @default.
• W4361954280 creator A5081773153 @default.
• W4361954280 creator A5082195410 @default.
• W4361954280 creator A5082520513 @default.
• W4361954280 creator A5083333226 @default.
• W4361954280 creator A5083605021 @default.
• W4361954280 creator A5084233435 @default.
• W4361954280 creator A5085170830 @default.
• W4361954280 creator A5085843094 @default.
• W4361954280 creator A5087646089 @default.
• W4361954280 creator A5091508616 @default.
• W4361954280 date "2023-04-01" @default.
• W4361954280 modified "2023-10-18" @default.
• W4361954280 title "Data from Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance" @default.
• W4361954280 doi "https://doi.org/10.1158/1078-0432.c.6532931.v1" @default.
• W4361954280 hasPublicationYear "2023" @default.
• W4361954280 type Work @default.
• W4361954280 citedByCount "0" @default.
• W4361954280 crossrefType "posted-content" @default.
• W4361954280 hasAuthorship W4361954280A5008174510 @default.
• W4361954280 hasAuthorship W4361954280A5012973903 @default.
• W4361954280 hasAuthorship W4361954280A5013805263 @default.
• W4361954280 hasAuthorship W4361954280A5018587370 @default.
• W4361954280 hasAuthorship W4361954280A5021169552 @default.
• W4361954280 hasAuthorship W4361954280A5021762206 @default.
• W4361954280 hasAuthorship W4361954280A5022677387 @default.
• W4361954280 hasAuthorship W4361954280A5023192928 @default.
• W4361954280 hasAuthorship W4361954280A5024721415 @default.
• W4361954280 hasAuthorship W4361954280A5028333558 @default.
• W4361954280 hasAuthorship W4361954280A5031229355 @default.
• W4361954280 hasAuthorship W4361954280A5033987639 @default.
• W4361954280 hasAuthorship W4361954280A5037908617 @default.
• W4361954280 hasAuthorship W4361954280A5040450413 @default.
• W4361954280 hasAuthorship W4361954280A5045263771 @default.
• W4361954280 hasAuthorship W4361954280A5047370165 @default.
• W4361954280 hasAuthorship W4361954280A5049869363 @default.
• W4361954280 hasAuthorship W4361954280A5053506379 @default.
• W4361954280 hasAuthorship W4361954280A5053924692 @default.
• W4361954280 hasAuthorship W4361954280A5055277039 @default.
• W4361954280 hasAuthorship W4361954280A5057710096 @default.
• W4361954280 hasAuthorship W4361954280A5058717267 @default.
• W4361954280 hasAuthorship W4361954280A5067794408 @default.
• W4361954280 hasAuthorship W4361954280A5069830252 @default.
• W4361954280 hasAuthorship W4361954280A5070823369 @default.
• W4361954280 hasAuthorship W4361954280A5071581968 @default.
• W4361954280 hasAuthorship W4361954280A5073423716 @default.
• W4361954280 hasAuthorship W4361954280A5076118281 @default.
• W4361954280 hasAuthorship W4361954280A5076784474 @default.
• W4361954280 hasAuthorship W4361954280A5077169627 @default.
• W4361954280 hasAuthorship W4361954280A5081773153 @default.
• W4361954280 hasAuthorship W4361954280A5082195410 @default.
• W4361954280 hasAuthorship W4361954280A5082520513 @default.
• W4361954280 hasAuthorship W4361954280A5083333226 @default.
• W4361954280 hasAuthorship W4361954280A5083605021 @default.
• W4361954280 hasAuthorship W4361954280A5084233435 @default.
• W4361954280 hasAuthorship W4361954280A5085170830 @default.
• W4361954280 hasAuthorship W4361954280A5085843094 @default.
• W4361954280 hasAuthorship W4361954280A5087646089 @default.
• W4361954280 hasAuthorship W4361954280A5091508616 @default.
• W4361954280 hasBestOaLocation W43619542802 @default.
• W4361954280 hasConcept C104317684 @default.
• W4361954280 hasConcept C121608353 @default.
• W4361954280 hasConcept C134935766 @default.
• W4361954280 hasConcept C182979987 @default.
• W4361954280 hasConcept C2778502085 @default.
• W4361954280 hasConcept C2779138821 @default.
• W4361954280 hasConcept C2779962180 @default.
• W4361954280 hasConcept C502942594 @default.
• W4361954280 hasConcept C530470458 @default.

• next